How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

8,087 results for

Peptic Ulcer Disease

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Prevention of Recurrent Ulcer Bleeding in Patients With Idiopathic Gastroduodenal Ulcer

Intervention/treatment Phase Active Peptic Ulcer Disease/GI Bleeding Drug: Misoprostol Oral Tablet Drug: Placebo Oral Tablet Phase 4 Detailed Description: HYPOTHESIS The hypothesis that a combination therapy of misoprostol and lansoprazole is superior to lansoprazole alone for the prevention of recurrent ulcer bleeding in patients with a history of idiopathic ulcer bleeding. STUDY DESIGN OVERVIEW It is a two-year, double blinded, randomized trial of a combination therapy with misoprostol with PPI (...) Numbers: NRT_MISO Study First Posted: September 18, 2018 Last Update Posted: September 19, 2018 Last Verified: September 2018 Layout table for additional information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Additional relevant MeSH terms: Layout table for MeSH terms Ulcer Hemorrhage Peptic Ulcer Pathologic Processes Duodenal Diseases Intestinal Diseases Gastrointestinal Diseases Digestive System Diseases Stomach Diseases Misoprostol Abortifacient

2018 Clinical Trials

182. A Study of Esomeplazole (D961H) in Japanese Paediatric Patients With Reflux Esophagitis, Gastric Ulcer or Duodenal Ulcer

ulcer Additional relevant MeSH terms: Layout table for MeSH terms Ulcer Gastroesophageal Reflux Esophagitis Stomach Ulcer Duodenal Ulcer Esophagitis, Peptic Pathologic Processes Esophageal Motility Disorders Deglutition Disorders Esophageal Diseases Gastrointestinal Diseases Digestive System Diseases Gastroenteritis Peptic Ulcer Duodenal Diseases Intestinal Diseases Stomach Diseases Esomeprazole Anti-Inflammatory Agents, Non-Steroidal Anti-Ulcer Agents Gastrointestinal Agents Proton Pump Inhibitors (...) -steroidal anti-inflammatory drugs or low-dose aspirin therapy group, Primary endpoints are evaluated at week 32. Further, this study is designed to evaluate the long term efficacy and safety of D961H for a maximum of 52 weeks, in consideration of the medical needs for long term proton pump inhibitor treatment. Patient can continue study treatment up to 52 weeks, if they want. Condition or disease Intervention/treatment Phase Reflux Esophagitis Gastric Ulcer Duodenal Ulcer Drug: D961H capsule 10mg Drug

2018 Clinical Trials

183. Peptic ulcer disease and heart disease are associated with periprosthetic fractures after total hip replacement. (PubMed)

Peptic ulcer disease and heart disease are associated with periprosthetic fractures after total hip replacement. There have been no published studies assessing the possible association of medical comorbidities with periprosthetic fracture risk. We therefore assessed whether medical comorbidity is associated with risk of periprosthetic fractures after total hip replacement (THR).We used prospectively collected data from 1989-2008 in the Mayo Clinic Total Joint Registry for 2 cohorts: primary THR (...) postoperative periprosthetic fractures in the primary THR cohort and 330 in the revision THR cohort. In patients who underwent primary THR, 2 comorbidities were associated with higher risk of periprosthetic fracture: peptic ulcer disease with adjusted hazard ratio of 1.5 (95% CI: 1.1-2.2) and heart disease with adjusted hazard ratio of 1.7 (CI: 1.2-2.4). In patients with revision THR, peptic ulcer disease was associated with a higher adjusted risk of periprosthetic fracture, 1.6 (CI: 1.1-2.3).Peptic ulcer

Full Text available with Trip Pro

2012 Acta Orthopaedica

184. Very long-term treatment of peptic ulcer with cimetidine. (PubMed)

Very long-term treatment of peptic ulcer with cimetidine. In an open trial, 96 patients with endoscopically proven peptic ulcers were randomly allocated to treatment with cimetidine (1 g/day) for periods of 3, 6, 9, or 12 months. After their courses of treatment, the patients were followed up for at least 6 months. In 92% the ulcers had healed after treatment for 1 month, and in a further 5% the ulcers healed during the next 2 months. Ulcers recurred during treatment in 24% of patients (...) and within 6 months of withdrawal of treatment in a further 43%. In nearly a third of patients the recurrences were asymptomatic and were discovered only through routine endoscopic studies. Continuous treatment with full doses of cimetidine for a year seems to prevent relapse of the majority of ulcers which have healed during treatment; but it does not cure the ulcer disease, since relapse generally occurs quite rapidly when treatment is discontinued.

1978 Lancet

185. Peptic Ulcer: Surgical Perspective (Diagnosis)

Peptic Ulcer: Surgical Perspective (Diagnosis) Peptic Ulcer Disease: Background, Anatomy, Pathophysiology Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMTgxNzUzLW92ZXJ2aWV3 processing > Peptic Ulcer Disease (...) Updated: Dec 21, 2018 Author: BS Anand, MD; Chief Editor: Philip O Katz, MD, FACP, FACG Share Email Print Feedback Close Sections Sections Peptic Ulcer Disease Overview Background Gastric and duodenal ulcers usually cannot be differentiated based on history alone, although some findings may be suggestive (see ). Epigastric pain is the most common symptom of both gastric and duodenal ulcers. It is characterized by a gnawing or burning sensation and occurs after meals—classically, shortly after meals

2014 eMedicine Pediatrics

186. Peptic Ulcer: Surgical Perspective (Follow-up)

Peptic Ulcer: Surgical Perspective (Follow-up) Peptic Ulcer Disease Treatment & Management: Approach Considerations, Bleeding Peptic Ulcers, H pylori Infection Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache (...) =aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMTgxNzUzLXRyZWF0bWVudA== processing > Peptic Ulcer Disease Treatment & Management Updated: Dec 21, 2018 Author: BS Anand, MD; Chief Editor: Philip O Katz, MD, FACP, FACG Share Email Print Feedback Close Sections Sections Peptic Ulcer Disease Treatment Approach Considerations The 2017 American College of Gastroenterology (ACG) guidelines for the treatment of H pylori infection (HPI) indicates that selection of an HPI management regimen should take into account any previous antibiotic exposure(s). The ACG also

2014 eMedicine Pediatrics

187. Peptic Ulcer: Surgical Perspective (Overview)

Peptic Ulcer: Surgical Perspective (Overview) Peptic Ulcer Disease: Background, Anatomy, Pathophysiology Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMTgxNzUzLW92ZXJ2aWV3 processing > Peptic Ulcer Disease (...) Updated: Dec 21, 2018 Author: BS Anand, MD; Chief Editor: Philip O Katz, MD, FACP, FACG Share Email Print Feedback Close Sections Sections Peptic Ulcer Disease Overview Background Gastric and duodenal ulcers usually cannot be differentiated based on history alone, although some findings may be suggestive (see ). Epigastric pain is the most common symptom of both gastric and duodenal ulcers. It is characterized by a gnawing or burning sensation and occurs after meals—classically, shortly after meals

2014 eMedicine Pediatrics

188. Peptic Ulcer: Surgical Perspective (Treatment)

Peptic Ulcer: Surgical Perspective (Treatment) Peptic Ulcer Disease Treatment & Management: Approach Considerations, Bleeding Peptic Ulcers, H pylori Infection Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache (...) =aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMTgxNzUzLXRyZWF0bWVudA== processing > Peptic Ulcer Disease Treatment & Management Updated: Dec 21, 2018 Author: BS Anand, MD; Chief Editor: Philip O Katz, MD, FACP, FACG Share Email Print Feedback Close Sections Sections Peptic Ulcer Disease Treatment Approach Considerations The 2017 American College of Gastroenterology (ACG) guidelines for the treatment of H pylori infection (HPI) indicates that selection of an HPI management regimen should take into account any previous antibiotic exposure(s). The ACG also

2014 eMedicine Pediatrics

189. The Peptic Ulcer Perforation (PULP) score: a predictor of mortality following peptic ulcer perforation. A cohort study. (PubMed)

The Peptic Ulcer Perforation (PULP) score: a predictor of mortality following peptic ulcer perforation. A cohort study. Accurate and early identification of high-risk surgical patients with perforated peptic ulcer (PPU) is important for triage and risk stratification. The objective of the present study was to develop a new and improved clinical rule to predict mortality in patients following surgical treatment for PPU.nationwide cohort study based on prospectively collected data.thirty-five (...) hospitals in Denmark.a total of 2668 patients surgically treated for gastric or duodenal PPU between 1 February 2003 and 31 August 2009.30-day mortality.We derived a new clinical prediction rule for 30-day mortality and evaluated and compared its prognostic performance with the American Society of Anaesthesiologists (ASA) and Boey scores. A total of 708 patients (27%) died within 30 days of surgery. The Peptic Ulcer Perforation (PULP) score - comprised eight variables with an adjusted odds ratio of more

2011 Acta Anaesthesiologica Scandinavica

190. Peptic ulcers after the Great East Japan earthquake and tsunami: possible existence of psychosocial stress ulcers in humans. (PubMed)

Peptic ulcers after the Great East Japan earthquake and tsunami: possible existence of psychosocial stress ulcers in humans. Societal stress derived from an event that affects the whole society, e. g., a natural disaster, provides a unique, indirect way of determining the relationship between psychological stress and peptic ulcer disease in humans. In this study, we investigated the changing patterns of the incidence of peptic ulcers before and after the Great East Japan earthquake, which (...) in the disease were observed after the Great East Japan earthquake. The significant increase in the proportion of non-H. pylori and non-NSAID ulcers after the earthquake indicated that psychological stress alone induced peptic ulcers in humans independently of H. pylori infection and NSAID intake.

2013 Journal of gastroenterology

191. Drug Use Surveillance of Takecab for "Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis"

information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Additional relevant MeSH terms: Layout table for MeSH terms Ulcer Gastroesophageal Reflux Esophagitis Stomach Ulcer Duodenal Ulcer Esophagitis, Peptic Pathologic Processes Esophageal Motility Disorders Deglutition Disorders Esophageal Diseases Gastrointestinal Diseases Digestive System Diseases Gastroenteritis Peptic Ulcer Duodenal Diseases Intestinal Diseases Stomach Diseases (...) provided by (Responsible Party): Takeda Study Details Study Description Go to Brief Summary: The purpose of this study is to evaluate the safety and efficacy of vonoprazan tablets (Takecab tablets) in patients with gastric ulcer, duodenal ulcer, and reflux esophagitis in the routine clinical setting. Condition or disease Intervention/treatment Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis Drug: Vonoprazan Detailed Description: The drug being tested in this study is called Vonoprazan (Takecab

2017 Clinical Trials

192. Special dr ug Use Surveillance of Takecab for "Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Non-steroidal Anti-inflammatory Drugs: Long-term Use"Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Non-stero

-5005 JapicCTI-163436 ( Registry Identifier: JapicCTI ) First Posted: July 11, 2017 Last Update Posted: February 15, 2019 Last Verified: February 2019 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: No Layout table for additional information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Additional relevant MeSH terms: Layout table for MeSH terms Ulcer Recurrence Duodenal Ulcer Pathologic Processes Disease Attributes Peptic Ulcer (...) Special dr ug Use Surveillance of Takecab for "Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Non-steroidal Anti-inflammatory Drugs: Long-term Use"Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Non-stero Special dr ug Use Surveillance of Takecab for "Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Non-steroidal Anti-inflammatory Drugs: Long-term Use"Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients

2017 Clinical Trials

193. A systematic review and meta-analysis of laparoscopic versus open repair for perforated peptic ulcer

A systematic review and meta-analysis of laparoscopic versus open repair for perforated peptic ulcer Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web (...) A sensitivity analysis is conducted to assess the impact of decisions taken in the review process on the meta-analysis outcome. These decisions may have been made in various stages of the review, e.g. the decision to exclude certain disease models, the decision to pool certain units of measurement for an outcome, the choice of effect measure, how subgroup variables are stratified etc. In order to assess the robustness of the findings of the meta-analysis, the analyses are re-run using the alternative

2017 PROSPERO

194. Eradication of Helicobacter pylori infection reduces the incidence of peptic ulcer disease in patients using nonsteroidal anti-inflammatory drugs: a meta-analysis.

Eradication of Helicobacter pylori infection reduces the incidence of peptic ulcer disease in patients using nonsteroidal anti-inflammatory drugs: a meta-analysis. To investigate the association between use of nonsteroidal anti-inflammatory drugs (NSAID) and Helicobacter pylori infection, interactive effect of H. pylori infection and NSAID use on the development of peptic ulcer disease (PUD), and the effect of H. pylori eradication therapy on PUD development.We performed a systematic literature (...) search in EMBASE and PubMed for relevant articles published in English between January 1989 and August 2010, with the following MeSH and/or key words: non-steroidal anti-inflammatory drugs, or NSAIDs, Helicobacter pylori, or H. pylori, peptic ulcer disease or PUD, and randomized-control study or clinical trial. The meta-analysis was conducted using the Review Manager 4.2.2.In the analysis of five studies, the pooled prevalence of H. pylori infection was 74.5% and 71.1% in NSAID users and non-NSAID

2012 Helicobacter

195. Chronic obstructive pulmonary disease: an independent risk factor for peptic ulcer bleeding: a nationwide population-based study. (PubMed)

Chronic obstructive pulmonary disease: an independent risk factor for peptic ulcer bleeding: a nationwide population-based study. Peptic ulcer bleeding remains a major healthcare problem despite decreasing prevalence of peptic ulcer disease. The role of chronic obstructive pulmonary disease (COPD) in the risk of peptic ulcer bleeding has not yet been established.To determine if COPD patients have a higher risk of peptic ulcer bleeding than the general population and to identify the risk factors (...) , by log-rank test). By Cox proportional hazard regression analysis, COPD [hazard ratio (HR) 1.93, 95% CI 1.73-2.17] was an independent risk factor after adjusting for age, gender, underlying comorbidities and ulcerogenic medication. Age > 65 years, male, comorbidities of hypertension, diabetes, heart failure, history of peptic ulcer disease, and chronic renal disease and use of nonsteroidal anti-inflammatory drugs were risk factors of ulcer bleeding in COPD patients.Patients with chronic obstructive

Full Text available with Trip Pro

2012 Alimentary Pharmacology & Therapeutics

196. The relative contribution of NSAIDs and H elicobacter pylori to the aetiology of endoscopically-diagnosed peptic ulcer disease: observations from a tertiary referral hospital in the UK between 2005 and 2010. (PubMed)

The relative contribution of NSAIDs and H elicobacter pylori to the aetiology of endoscopically-diagnosed peptic ulcer disease: observations from a tertiary referral hospital in the UK between 2005 and 2010. Recent data from Western countries indicate that the aetiology of peptic ulcer disease (PUD) is changing as the prevalence of Helicobacter pylori is decreasing while the use of low-dose aspirin (LDA, ≤325 mg/day) is increasing.To investigate the changing aetiology and demographics of PUD (...) (for continuous variables).Overall, 386 patients were enrolled; 57% used NSAIDs (51% LDA only) and 43% were non-users. 57% of the whole cohort was H. pylori-positive (including 66% with duodenal ulcers and 47% with gastric ulcers). Compared with non-users, NSAID-users were older (mean age 68 vs. 61 years) and fewer were H. pylori-positive (52% vs. 63%). LDA-users were older (mean age 71 vs. 62 years) and more likely to be H. pylori-positive (61% vs. 41%) than those using non-aspirin NSAIDs. Twelve per cent

Full Text available with Trip Pro

2012 Alimentary Pharmacology & Therapeutics

197. Rabeprazole reduces the recurrence risk of peptic ulcers associated with low-dose aspirin in patients with cardiovascular or cerebrovascular disease: a prospective randomized active-controlled trial. (PubMed)

Rabeprazole reduces the recurrence risk of peptic ulcers associated with low-dose aspirin in patients with cardiovascular or cerebrovascular disease: a prospective randomized active-controlled trial. Patients using low-dose aspirin (LDA) have an increased risk of gastroduodenal mucosal lesions and upper gastrointestinal symptoms. We aimed to clarify the efficacy of rabeprazole for preventing peptic ulcer, esophagitis, and gastrointestinal symptoms associated with LDA.Patients with a history (...) of peptic ulcers who were receiving LDA for cardiovascular or cerebrovascular disease were randomly assigned to receive rabeprazole at 10 mg daily, rabeprazole at 20 mg daily, or gefarnate (a cytoprotective anti-ulcer agent) at 50 mg twice daily. The primary endpoint was the development of gastric and/or duodenal ulcer at 12 weeks. The modified Lanza score (MLS) and gastrointestinal symptoms were evaluated at baseline and at 12 weeks.The full analysis set comprised 261 patients (rabeprazole 10 mg: n

2012 Journal of gastroenterology

198. Association between interleukin-8 gene -251 T/A polymorphism and the risk of peptic ulcer disease: a meta-analysis. (PubMed)

Association between interleukin-8 gene -251 T/A polymorphism and the risk of peptic ulcer disease: a meta-analysis. It remains controversial regarding the association between interleukin-8 (IL-8) gene -251 T/A polymorphism and peptic ulcer disease (PUD) risk. Thus, a large-scale meta-analysis evaluating the precise association between this gene variant and PUD risk is required. We searched the PubMed, Embase, Web of Science, and Google Scholar until April 25, 2012. Additionally, hand searching (...) , 95% CI = 0.95-1.67, p = 0.113). However, in the subgroup analyses by ethnicity, H. pylori infection and the subtype of PUD, significant associations were found between IL-8 gene -251 T/A polymorphism and PUD risk in Asians, H. pylori+, duodenal ulcer disease (DUD) and gastric ulcer disease (GUD), respectively. In summary, the present meta-analysis suggests that IL-8 gene -251 T/A polymorphism is associated with increased PUD risk among Asians, and especially for the subgroups of H. pylori+, DUD

2012 Human immunology

199. Peptic Ulcer Disease

Peptic Ulcer Disease Peptic Ulcer Disease Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Peptic Ulcer Disease Peptic Ulcer Disease (...) Aka: Peptic Ulcer Disease , PUD , Gastric Ulcer , Duodenal Ulcer From Related Chapters II. Epidemiology : 500,000 cases per year in U.S. III. Etiologies Nonsteroidal Antiinflammatory Drugs ( s) Peptic ulcers occur in 5-20% of longterm use Duodenal Ulcer: 90-100% Gastric Ulcer: 70-90% Acid Induced Ulcers Idiopathic Zollinger-Ellison Syndrome Chronic Disease s in chronic debilitated conditions Systemic Mastocytosis ic IV. Risk Factors See V. Symptoms Duodenal Ulcer Mid- , deep recurring ache

2015 FP Notebook

200. Validation and psychometric properties of Chinese version of SF-36 in patients with hypertension, coronary heart diseases, chronic gastritis and peptic ulcer. (PubMed)

Validation and psychometric properties of Chinese version of SF-36 in patients with hypertension, coronary heart diseases, chronic gastritis and peptic ulcer. The SF-36 is widely used as a significant health outcome or quality of life indicator and validated in many languages versions including Chinese. But the Chinese version of the SF-36 (CSF-36) is rarely used for those patients with hypertension, coronary heart diseases, chronic gastritis and peptic ulcer in China. Therefore, the CSF-36 (...) needs to be validated in patients with chronic diseases.This paper is aimed to validate the CSF-36 using an in-patient sample of four chronic diseases from mainland China, with focusing on psychometric properties.The CSF-36 was used in a longitudinal study consisting of 534 patients in these four chronic disease groups. The psychometric properties of the scale were evaluated by indicators such as validity and reliability coefficients Cronbach α, Pearson r, standardized response mean employing

2012 International journal of clinical practice

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>